Why did ALCJ.PA stock rise intraday today?

ALCJ.PA stock rose on 06 Jan 2026 driven by a volume surge to 305,442 shares, technical momentum above the 50-day average, and renewed sector attention. Market chatter referenced Crossject’s ZENEO platform and relative sector comparisons on Investing.com.

What are the main risks for ALCJ.PA stock investors?

Key risks include negative EPS **-0.22**, reliance on external financing, clinical trial execution, and small-cap volatility. The company’s trailing PE is **-10.84**, reflecting losses and higher investment risk compared with larger Healthcare peers.

What is Meyka AI’s short-term forecast for ALCJ.PA stock?

Meyka AI's forecast model projects a monthly target of **EUR 2.00**, implying about **-15.97%** from today’s **EUR 2.38**. Forecasts are model-based projections and not guarantees.

Where is ALCJ.PA listed and which currency applies?

Crossject SA (ALCJ.PA) is listed on **EURONEXT** in Europe and quoted in **EUR**. The stock’s market cap is approximately **EUR 123,686,305.00** and shares outstanding are **51,860,086.00**.

EU Stocks

ALCJ.PA rises 10.96% intraday on 06 Jan 2026: watch EUR 2.40 high for momentum

ByHuzaifa Zahoor January 6, 2026January 6, 2026

ALCJ.PA stock led EURONEXT top gainers on 06 Jan 2026, rising 10.96% to EUR 2.38 intraday on higher volume. The intraday range ran from EUR 2.07 to a day high of EUR 2.40 on volume 305,442, above the 50-day average of 247,199 shares. Crossject SA (ALCJ.PA) gains came amid renewed investor focus on its needle-free ZENEO platform and higher short-term momentum in the Healthcare sector in Europe.